
MSD has revealed its intention to acquire biopharma firm ArQule in a deal worth a potential total of $2.7 billion, …
Daiichi Sankyo and biotech firm Arqule are to move their lung cancer treatment ARQ 197 into phase III trials. The …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

